Project: Sialylated antigens as immune tolerance inducers: an innovative therapeutic vaccine for MS.
SIAGEN-MS will develop a therapeutic vaccine against Multiple Sclerosis (MS) by modification of myelin-derived peptides through sialylation. The Eurostars project will deliver 1) A sialylated antigen-based therapeutic vaccine that is able to target dendritic cells and/or microglia, 2) in vivo evidence that the therapeutic vaccine is able to slow and inhibit progress of MS, 3) initiated preclinical toxicology and safety assessments.
| Acronym | SIAGEN-MS (Reference Number: 9059) |
| Duration | 01/01/2015 - 01/01/2018 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 1 |